OrbiMed discloses 1.5% C4 Therapeutics (NASDAQ: CCCC) ownership

Rhea-AI Filing Summary

C4 Therapeutics, Inc. received an amended Schedule 13G/A showing updated ownership by OrbiMed entities. OrbiMed Advisors LLC reports beneficial ownership of 521,368 shares of common stock, representing 0.5% of the class. OrbiMed Capital LLC reports 883,534 shares, or 1.0% of the class.

Together, the reporting persons hold 1.5% of C4 Therapeutics’ common stock on behalf of other persons who have rights to dividends or sale proceeds. Investment and voting power is exercised through a management committee, whose individual members disclaim beneficial ownership. The securities are described as acquired and held in the ordinary course of business, not to influence control.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

C4 Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

12529R107

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 12529R107

1

Names of Reporting Persons

OrbiMed Advisors LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 521,368.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 521,368.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

521,368.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.5 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP No. 12529R107

1

Names of Reporting Persons

OrbiMed Capital LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 883,534.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 883,534.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

883,534.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

1.0 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: C4 Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 490 Arsenal Way, Suite 120 Watertown, MA 02472
Item 2.
(a)	Name of person filing: OrbiMed Advisors LLC OrbiMed Capital LLC
(b)	Address or principal business office or, if none, residence: 601 Lexington Avenue, 54th Floor New York, NY 10022
(c)	Citizenship: Please refer to Item 4 on each cover sheet for each filing person.
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 12529R107
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: OrbiMed Advisors LLC: 521,368 OrbiMed Capital LLC: 883,534
(b)	Percent of class: OrbiMed Advisors LLC: 0.5% OrbiMed Capital LLC: 1.0%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: OrbiMed Advisors LLC: 0 OrbiMed Capital LLC: 883,534
	(ii) Shared power to vote or to direct the vote: OrbiMed Advisors LLC: 521,368 OrbiMed Capital LLC: 0
	(iii) Sole power to dispose or to direct the disposition of: OrbiMed Advisors LLC: 0 OrbiMed Capital LLC: 883,534
	(iv) Shared power to dispose or to direct the disposition of: OrbiMed Advisors LLC: 521,368 OrbiMed Capital LLC: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Reporting Persons hold 1.5% of the shares of Common Stock in the aggregate on behalf of other persons who have the right to receive or the power to direct the receipt of dividends from, or proceeds from the sale of, such securities. OrbiMed Advisors LLC and OrbiMed Capital LLC exercise investment and voting power over the shares of Common Stock through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares of Common Stock reported herein.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

OrbiMed Advisors LLC

Signature:	/s/ Carl L. Gordon
Name/Title:	Carl L. Gordon/Member
Date:	02/17/2026

OrbiMed Capital LLC

Signature:	/s/ Carl L. Gordon
Name/Title:	Carl L. Gordon/Member
Date:	02/17/2026

FAQ

What ownership stake in C4 Therapeutics (CCCC) does OrbiMed report?

OrbiMed entities report an aggregate 1.5% stake in C4 Therapeutics’ common stock. OrbiMed Advisors LLC holds 521,368 shares (0.5%), and OrbiMed Capital LLC holds 883,534 shares (1.0%), all beneficially owned on behalf of other persons with economic rights.

Who are the reporting persons in the C4 Therapeutics (CCCC) Schedule 13G/A?

The reporting persons are OrbiMed Advisors LLC and OrbiMed Capital LLC. Both are Delaware entities with a principal business office at 601 Lexington Avenue, 54th Floor, New York, NY 10022, and they jointly report beneficial ownership of C4 Therapeutics common stock.

Does OrbiMed seek to influence control of C4 Therapeutics (CCCC) with this stake?

The filing states the securities were acquired and are held in the ordinary course of business. It further certifies they were not acquired and are not held for the purpose or effect of changing or influencing control of C4 Therapeutics.

How much voting and dispositive power does OrbiMed have over C4 Therapeutics (CCCC) shares?

OrbiMed Advisors LLC has shared voting and dispositive power over 521,368 shares, with no sole power. OrbiMed Capital LLC has sole voting and dispositive power over 883,534 shares, with no shared power, as detailed in the ownership section.

On whose behalf does OrbiMed hold its C4 Therapeutics (CCCC) position?

The filing explains that OrbiMed Advisors LLC and OrbiMed Capital LLC hold 1.5% of C4 Therapeutics’ common stock on behalf of other persons. Those persons have rights to receive dividends or proceeds from any sale of the reported securities.

What is the event date for OrbiMed’s C4 Therapeutics (CCCC) ownership report?

The Schedule 13G/A indicates an event date of December 31, 2025. This date reflects when the ownership information became reportable under the applicable rules, leading to the Amendment No. 3 filing for C4 Therapeutics’ common stock.